rexresearch.com
Jerome CANADY, et al.
CAP vs Cancer
https://www.purdue.edu/newsroom/releases/2019/Q3/treat-cancer-with-cold-plasma-purdue-aerospace-engineer-helps-bring-first-clinical-trial.html
August 19, 2019
Treat cancer with cold plasma? Purdue
aerospace engineer helps bring first clinical trial
by Kayla Wiles
Cold atmospheric plasma technology, currently the only way to
remove microscopic cancer tumors remaining from surgery, has been
approved by the U.S. Food and Drug Administration for first-ever
use in a clinical trial.
For solid tumor cancers such as those in the breast and lungs,
standard treatment involves chemotherapy, radiation, surgery or
all of the above. When these tumors aren’t fully removed, they can
cause the cancer to come back. Approximately 20%-40% of women
undergoing partial mastectomy in the U.S. each year, for example,
return to surgery because of marginal tumors that the surgeon
couldn’t see the first time around.
A multi-institute team, which included Purdue University aerospace
engineer Alexey Shashurin, developed a pen-like electrosurgical
scalpel that sprays a blue jet of cold plasma at any remaining
cancerous tissue or cells for 2-7 minutes. The device targets only
tumors, leaving surrounding tissue unharmed, as demonstrated in
vitro, in vivo and in FDA-approved compassionate use cases prior
to the clinical trial.
U.S. Medical Innovations LLC (USMI) and the Jerome Canady Research
Institute for Advanced Biological and Technological Sciences
(JCRI/ABTS) led the team and are sponsoring the clinical trial,
with plans to recruit patients in September.
USMI developed and patented the first high-frequency
electrosurgical generator with cold plasma for the selective
treatment of cancer in 2014.
The technology, approved for an FDA phase I clinical trial in 20
patients, was developed by a team led by Canady, chief science
officer of JCRI/ABTS, CEO of USMI and a research professor in the
School of Engineering and Applied Sciences at The George
Washington University; an engineering team led by Taisen Zhuang,
the vice president of research and development at USMI; Michael
Keidar, a professor in the School of Engineering and Applied
Sciences and director of the Micropropulsion and Nanotechnology
lab at The George Washington University; and Shashurin, an
assistant professor in Purdue’s School of Aeronautics and
Astronautics.
“Plasmas are very reactive, which can cause a variety of responses
on the cellular level in biological tissue. But because they’re
also extremely hot gases, there had been a push over the past 20
years to generate and test cold plasmas for biological
applications,” Shashurin said.
In addition to developing cold plasma solutions for cancer
treatment technology, Shashurin’s lab also conducts research on
various topics of experimental plasma sciences. These include
generation and diagnostics of miniature cold plasmas at
atmospheric pressure, application of cold plasma for
sterilization, laser-induced plasma for combustion diagnostics,
advanced spacecraft propulsion and nanosecond repetitive plasma
discharges for aerodynamic flow control.
In 2008, Keidar and Shashurin were among an early wave of
researchers to develop a cold plasma generator and see that it
produces responses from biological tissue. By 2011, the team had
published a paper in the British Journal of Cancer showing that
cold plasma selectively kills cancer cells in animal models.
Keidar and Shashurin began consulting with USMI in 2013 on
creating an industrial-scale prototype of the cold plasma
generator and its application for cancer treatment, based on a
generator they had developed and patented. The goal was to
integrate cold plasma with Canady Hybrid Plasma electrosurgical
scalpels already used in operating rooms because these scalpels
allow for bloodless surgery. This is due to their ability to cut
and coagulate tissue at the same time, sealing off blood vessels.
This cold plasma technology selectively kills tumors through toxic
molecules called reactive oxygen species, which damage targeted
cancerous tissue but do not affect normal biological tissue.
Lasers could also kill tissue, but the high heat would also bring
permanent damage to surrounding tissue.
To bridge the advantages of electrosurgical scalpels with cold
plasma, JCRI/ABTS and USMI converted standard high-frequency
electrosurgical generators into ones that spray cold plasma.
“Cold plasma application is the fourth arm for the treatment of
cancer, following chemotherapy, radiation and surgery. There’s no
other ‘magic bullet’ out there for killing off residual tissue,”
Canady said.
One of the clinical trial sites for this device will be Rush
University in Chicago. Meanwhile, Shashurin’s lab at Purdue will
continue to collaborate with USMI on further development of this
technology.
The work aligns with Purdue's Giant Leaps celebration,
acknowledging the university’s global advancements made in health,
longevity and quality of life as part of Purdue’s 150th
anniversary. This is one of the four themes of the yearlong
celebration’s Ideas Festival, designed to showcase Purdue as an
intellectual center solving real-world issues.
https://jhu.pure.elsevier.com/en/publications/the-effect-of-cold-atmospheric-plasma-treatment-on-cancer-stem-ce-3
The effect of cold atmospheric plasma
treatment on cancer stem cells
Barry Trink, Michael Keidar, Jerome Canady, Yeela Shamai,
Maty Tzukerman
Abstract
Intratumoral heterogeneity challenges existing paradigms for
anticancer therapy. Accumulating evidence demonstrates that the
model of cancer stem cells (CSCs) and the model of clonal
evolution mutually contribute to intratumoral heterogeneity, as
CSCs themselves undergo clonal evolution. The limitation of
conventional anticancer therapies may lead to treatment failure
and cancer recurrence, mainly due to drug resistance and
self-renewal capacities of CSC. These two factors are responsible
for resistance to standard oncology treatments. In this study, we
examine cold atmospheric plasma (CAP) treatment of CSC in vitro.
We demonstrate that two types of heterogeneous CSC populations
derived from a single patient tumor are sensitive to the effects
of plasma treatment. Surprisingly, the more aggressive CSC
population (C13) was more sensitive to CAP treatment than the less
aggressive type (C12).
https://arxiv.org/pdf/1804.08421
Micro-sized cold atmospheric plasmasource
for brain and breast cancer treatment
Zhitong Chen, Li Lin, Qinmin Zheng, Jonathan H.Sherman,
Jerome Canady, Barry Trink, Michael Keidar
Abstract
Micro-sized cold atmospheric plasma (μCAP) has been developedt o
expand the applications of CAP in cancer therapy. In this paper,
μCAP devices with different nozzle lengths were applied to
investigate effects on both brain (glioblastoma
U87) and breast (MDA-MB-231)cancer cells.
Various diagnostic techniques were employed to evaluate the
parameters of μCAP devices with different lengths such as
potential distribution, electron density, and optical emission
spectroscopy. The generation of short-and long-lived species (such
as hydroxyl radical (OH), superoxide (O2-), hydrogen
peroxide (H2O2), nitrite (NO2-), et
al) were studied. These data
revealed that μCAP treatment with a 20 mm length tube
has a stronger effect than that of the 60 mm tube due to the
synergetic effects of reactive species and free
radicals. Reactive species generated
by μCAP enhanced tumor cell death in a dose-dependent
fashion and was not specific with regards to tumor cell type.
https://www.nature.com/articles/srep18339
Scientific Reports volume 5, Article number: 18339 (2015)
Principles of using Cold Atmospheric Plasma
Stimulated Media for Cancer Treatment
Dayun Yan, et al.
Abstract
To date, the significant anti-cancer capacity of cold
atmospheric plasma (CAP) on dozens of cancer cell lines has been
demonstrated in vitro and in mice models. Conventionally, CAP was
directly applied to irradiate cancer cells or tumor tissue. Over
past three years, the CAP irradiated media was also found to kill
cancer cells as effectively as the direct CAP treatment. As a
novel strategy, using the CAP stimulated (CAPs) media has become a
promising anti-cancer tool. In this study, we demonstrated several
principles to optimize the anti-cancer capacity of the CAPs media
on glioblastoma cells and breast cancer cells. Specifically, using
larger wells on a multi-well plate, smaller gaps between the
plasma source and the media and smaller media volume enabled us to
obtain a stronger anti-cancer CAPs media composition without
increasing the treatment time. Furthermore, cysteine was the main
target of effective reactive species in the CAPs media.
Glioblastoma cells were more resistant to the CAPs media than
breast cancer cells. Glioblastoma cells consumed the effective
reactive species faster than breast cancer cells did. In contrast
to nitric oxide, hydrogen peroxide was more likely to be the
effective reactive species.
https://www.mdpi.com/2072-6694/9/6/61
A Novel Micro Cold Atmospheric Plasma
Device for Glioblastoma Both In Vitro and In Vivo
by Zhitong Chen, et al.
Abstract
Cold atmospheric plasma (CAP) treatment is a rapidly expanding
and emerging technology for cancer treatment. Direct CAP jet
irradiation is limited to the skin and it can also be invoked as a
supplement therapy during surgery as it only causes cell death in
the upper three to five cell layers. However, the current cannulas
from which the plasma emanates are too large for intracranial
applications. To enhance efficiency and expand the applicability
of the CAP method for brain tumors and reduce the gas flow rate
and size of the plasma jet, a novel micro-sized CAP device (µCAP)
was developed and employed to target glioblastoma tumors in the
murine brain. Various plasma diagnostic techniques were applied to
evaluate the physics of helium µCAP such as electron density,
discharge voltage, and optical emission spectroscopy (OES). The
direct and indirect effects of µCAP on glioblastoma
(U87MG-RedFluc) cancer cells were investigated in vitro. The
results indicate that µCAP generates short- and long-lived species
and radicals (i.e., hydroxyl radical (OH), hydrogen peroxide
(H2O2), and nitrite (NO2−), etc.) with increasing tumor cell death
in a dose-dependent manner. Translation of these findings to an in
vivo setting demonstrates that intracranial µCAP is effective at
preventing glioblastoma tumor growth in the mouse brain. The µCAP
device can be safely used in mice, resulting in suppression of
tumor growth. These initial observations establish the µCAP device
as a potentially useful ablative therapy tool in the treatment of
glioblastoma.
https://www.researchgate.net/publication/256614357_Cold_Atmospheric_Plasma_for_Selectively_Ablating_Metastatic_Breast_Cancer_Cells
PLoS ONE 8(9):e73741 · September 2013
Cold Atmospheric Plasma for Selectively
Ablating Metastatic Breast Cancer Cells
Mian Wang, et al.
Abstract
Traditional breast cancer treatments such as surgery and
radiotherapy contain many inherent limitations with regards to
incomplete and nonselective tumor ablation. Cold atomospheric
plasma (CAP) is an ionized gas where the ion temperature is close
to room temperature. It contains electrons, charged particles,
radicals, various excited molecules, UV photons and transient
electric fields. These various compositional elements have the
potential to either enhance and promote cellular activity, or
disrupt and destroy them. In particular, based on this unique
composition, CAP could offer a minimally-invasive surgical
approach allowing for specific cancer cell or tumor tissue removal
without influencing healthy cells. Thus, the objective of this
research is to investigate a novel CAP-based therapy for
selectively bone metastatic breast cancer treatment. For this
purpose, human metastatic breast cancer (BrCa) cells and bone
marrow derived human mesenchymal stem cells (MSCs) were separately
treated with CAP, and behavioral changes were evaluated after 1,
3, and 5 days of culture. With different treatment times,
different BrCa and MSC cell responses were observed. Our results
showed that BrCa cells were more sensitive to these CAP treatments
than MSCs under plasma dose conditions tested. It demonstrated
that CAP can selectively ablate metastatic BrCa cells in vitro
without damaging healthy MSCs at the metastatic bone site. In
addition, our study showed that CAP treatment can significantly
inhibit the migration and invasion of BrCa cells. The results
suggest the great potential of CAP for breast cancer therapy.
https://www.mdpi.com/2571-6182/1/1/19
Plasma 2018, 1(1), 218-228
https://doi.org/10.3390/plasma1010019
Treatment of Triple-Negative Breast Cancer
Cells with the Canady Cold Plasma Conversion System:
Preliminary Results
by Xiaoqian Cheng, et al.
Abstract
Triple-negative breast cancer is a phenotype of breast cancer
where the expression level of estrogen, progesterone and human
epidermal growth factor receptor 2 (HER2) receptors are low or
absent. It is more frequently diagnosed in younger and
premenopausal women, among which African and Hispanic have a
higher rate. Cold atmospheric plasma has revealed its promising
ant-cancer capacity over the past two decades. In this study, we
report the first cold plasma jet delivered by the Canady Cold
Plasma Conversion Unit and characterization of its electric and
thermal parameters. The unit effectively reduced the viability of
triple-negative breast cancer up to 80% without thermal damage,
providing a starting point for future clinical trials.
https://www.nature.com/articles/s41598-018-33914-w
Scientific Reports volume 8, Article number: 15418 (2018)
The Cell Activation Phenomena in the Cold
Atmospheric Plasma Cancer Treatment
Dayun Yan, et al.
Abstract
Cold Atmospheric Plasma (CAP) is an ionized gas with a near
room temperature. CAP is a controllable source for reactive
species, neutral particles, electromagnetic field and UV
radiation. CAP showed the promising application in cancer
treatment through the demonstration in vitro and in vivo. In this
study, we first demonstrate the existence of an activation state
on the CAP-treated cancer cells, which drastically decreases the
threshold of cell vulnerability to the cytotoxicity of the
CAP-originated reactive species such as H2O2 and NO2−. The
cytotoxicity of CAP treatment is still dependent on the
CAP-originated reactive species. The activation state of cancer
cells will not cause noticeable cytotoxicity. This activation is
an instantaneous process, started even just 2 s after the CAP
treatment begins. The noticeable activation on the cancer cells
starts 10–20 s during the CAP treatment. In contrast, the
de-sensitization of activation takes 5 hours after the CAP
treatment. The CAP-based cell activation explains the mechanism by
which direct CAP treatment causes a much stronger cytotoxicity
over the cancer cells compared with an indirect CAP treatment do,
which is a key to understand what the effect of CAP on cancer
cells.
https://www.researchgate.net/publication/258595094_Cold_Atmospheric_Plasma_in_Cancer_Therapy
October 2012
Cold Atmospheric Plasma in Cancer Therapy
Michael Keidar, et al.
Abstract
Plasma is an ionized gas that is typically generated in
high-temperature laboratory conditions. Recent progress in
atmospheric plasmas led to the creation of cold plasmas with ion
temperature close to room temperature. Areas of potential
application of cold atmospheric plasmas (CAP) include dentistry,
drug delivery, dermatology, cosmetics, wound healing, cellular
modifications, and cancer treatment. Various diagnostic tools have
been developed for characterization of CAP including intensified
charge-coupled device cameras, optical emission spectroscopy and
electrical measurements of the discharge propertied. Recently a
new method for temporally resolved measurements of absolute values
of plasma density in the plasma column of small-size atmospheric
plasma jet utilizing Rayleigh microwave scattering was proposed
[1,2]. In this talk we overview state of the art of CAP
diagnostics and understanding of the mechanism of plasma action of
biological objects. The efficacy of cold plasma in a pre-clinical
model of various cancer types (long, bladder, and skin) was
recently demonstrated [3]. Both in-vitro and in-vivo studies
revealed that cold plasmas selectively kill cancer cells. We
showed that: (a) cold plasma application selectively eradicates
cancer cells in vitro without damaging normal cells. For instance
a strong selective effect was observed; the resulting 60--70% of
lung cancer cells were detached from the plate in the zone treated
with plasma, whereas no detachment was observed in the treated
zone for the normal lung cells under the same treatment
conditions. (b) Significantly reduced tumor size in vivo. Cold
plasma treatment led to tumor ablation with neighbouring tumors
unaffected. These experiments were performed on more than 10 mice
with the same outcome. We found that tumors of about 5mm in
diameter were ablated after 2 min of single time plasma treatment.
The two best known cold plasma effects, plasma-induced apoptosis
and the decrease of cell migration velocity can have important
implications in cancer treatment by localizing the affected area
of the tissue and by decreasing metastasic development. In
addition, cold plasma treatment has affected the cell cycle of
cancer cells. In particular, cold plasma induces a 2-fold increase
in cells at the G2/M-checkpoint in both papilloma and carcinoma
cells at about 24 hours after treatment, while normal epithelial
cells (WTK) did not show significant differences. It was shown
that reactive oxygen species metabolism and oxidative stress
responsive genes are deregulated. We investigated the production
of reactive oxygen species (ROS) with cold plasma treatment as a
potential mechanism for the tumor ablation observed.
https://doi.org/10.3390/cancers11050671
Cancers 2019, 11(5), 671
Acidification is an Essential Process of
Cold Atmospheric Plasma and Promotes the Anti-Cancer Effect on
Malignant Melanoma Cells
by Christin Schneider, et al.
Abstract
(1) Background: Cold atmospheric plasma (CAP) is ionized gas
near room temperature. The anti-cancer effects of CAP were
confirmed for several cancer types and were attributed to
CAP-induced reactive species. However, the mode of action of CAP
is still not well understood. (2) Methods: Changes in cytoplasmic
Ca2+ level after CAP treatment of malignant melanoma cells were
analyzed via the intracellular Ca2+ indicator fura-2 AM.
CAP-produced reactive species were determined by fluorescence
spectroscopic and protein nitration by Western Blot analysis. (3)
Results: CAP caused a strong acidification of water and solutions
that were buffered with the so-called Good buffers, while
phosphate-buffered solutions with higher buffer capacity showed
minor pH reductions. The CAP-induced Ca2+ influx in melanoma cells
was stronger in acidic pH than in physiological conditions. NO
formation that is induced by CAP was dose- and pH-dependent and
CAP-treated solutions only caused protein nitration in cells under
acidic conditions. (4) Conclusions: We describe the impact of
CAP-induced acidification on the anti-cancer effects of CAP. A
synergistic effect of CAP-induced ROS, RNS, and acidic conditions
affected the intracellular Ca2+ level of melanoma cells. As the
microenvironment of tumors is often acidic, further acidification
might be one reason for the specific anti-cancer effects of CAP.
US2019274747
System and Method for Treating Cancer Through DNA Damage With
Cold Atmospheric Plasma With Self-organized Patterns
[ PDF ]
BACKGROUND OF THE INVENTION
Field of the Invention
[0004] The present invention relates to systems and methods for
using Cold Atmospheric Plasma (“CAP”) to treat cancer.
Brief Description of the Related Art
[0005] Breast cancer is one of the most common cancers diagnosed
among American women (excluding skin cancers), which is the second
leading cause of cancer death among women after lung cancer. See,
C. E. DeSantis, J. Ma, A. Goding Sauer, L. A. Newman, A. Jemal,
Breast cancer statistics, 2017, racial disparity in mortality by
state, CA: a cancer journal for clinicians 67(6) (2017) 439-448.
The global burden of breast cancer exceeds all other cancers and
the incidence rates of breast cancer are increasing. A. Jemal, R.
Siegel, J. Xu, E. Ward, Cancer statistics, 2010, CA: a cancer
journal for clinicians 60(5) (2010) 277-300. Different treatment
methods including surgical techniques, medication drugs, and
radiation-based approaches are routinely being used for breast
cancer. L. Hutchinson, Breast cancer: Challenges, controversies,
breakthroughs, Nature Reviews Clinical Oncology 7 (2010) 669-670.
However, additional treatment modalities need to be developed to
minimize the morbidity and mortality associated with this disease.
Breast cancer represent a multitude of different diseases with
intratumoral and intertumoral genetic and epigenetic alterations.
[0006] Plasma medicine is emerging as an innovative field for
cancer therapy, which combines biology, chemistry, plasma, and
medicine. See, G. Fridman, G. Friedman, A. Gutsol, A. B. Shekhter,
V. N. Vasilets, A. Fridman, Applied plasma medicine, Plasma
Processes and Polymers 5(6) (2008) 503-533 and M. Keidar, Plasma
for cancer treatment, Plasma Sources Science and Technology 24(3)
(2015) 033001. Plasma is one of the four fundamental states of
matter, and is a fully or partially ionized gas. See, M. Keidar,
A. Shashurin, O. Volotskova, M. Ann Stepp, P. Srinivasan, A.
Sandler, B. Trink, Cold atmospheric plasma in cancer therapy,
Physics of Plasmas 20(5) (2013) 057101. Historically, plasma could
be generated only at high temperatures or in vacuum, while more
recent studies have reported on plasma generated at atmospheric
pressure and at room temperature (cold atmospheric plasma, CAP).
See, E. Stoffels, Y. Sakiyama, D. B. Graves, Cold atmospheric
plasma: charged species and their interactions with cells and
tissues, IEEE Transactions on Plasma Science 36(4) (2008)
1441-1457; S. B. Karki, T. T. Gupta, E. Yildirim-Ayan, K. M.
Eisenmann, H. Ayan, Investigation of non-thermal plasma effects on
lung cancer cells within 3D collagen matrices, Journal of Physics
D: Applied Physics 50(31) (2017) 315401; and S. B. Karki, E.
Yildirim-Ayan, K. M. Eisenmann, H. Ayan, Miniature dielectric
barrier discharge nonthermal plasma induces apoptosis in lung
cancer cells and inhibits cell migration, BioMed research
international 2017 (2017).
[0007] CAP has attracted a lot of attentions because of its
remarkable potential to affect biological processes. Yan, D.;
Sherman, J. H.; Cheng, X.; Ratovitski, E.; Canady, J.; Keidar, M.
Controlling plasma stimulated media in cancer treatment
application. Appl. Phys. Lett. 2014, 105, 224101. The potential of
CAP in diverse bio-medical applications has been explored,
including wound treatments, blood coagulation, disinfection,
control of inflammation, regenerative medicine, and cancer
therapy. Z. Chen, H. Simonyan, X. Cheng, E. Gjika, L. Lin, J.
Canady, J. H. Sherman, C. Young, M. Keidar, A novel micro cold
atmospheric plasma device for glioblastoma both in vitro and in
vivo, Cancers 9(6) (2017) 61. The efficacy of CAP in the proposed
applications relies on the synergistic action of the reactive
oxygen species (ROS), reactive nitrogen species (RNS), free
radicals, ultraviolet (UV) photons, charged particles, and
electric fields. See, S. B. Karki, T. T. Gupta, E. Yildirim-Ayan,
K. M. Eisenmann, H. Ayan, Investigation of non-thermal plasma
effects on lung cancer cells within 3D collagen matrices, Journal
of Physics D: Applied Physics 50(31) (2017) 315401 and O.
Volotskova, T. S. Hawley, M. A. Stepp, M. Keidar, Targeting the
cancer cell cycle by cold atmospheric plasma, Scientific reports 2
(2012) 636.
[0008] ROS and RNS, combined or independently, are known to
promote cell proliferation as well as cell death, additionally,
extreme amounts of ROS and RNS may lead to the damage of proteins,
lipids, senescence and induce apoptosis. P. Attri, T. Sarinont, M.
Kim, T. Amano, K. Koga, A. E. Cho, E. H. Choi, M. Shiratani,
Influence of ionic liquid and ionic salt on protein against the
reactive species generated using dielectric barrier discharge
plasma, Scientific reports 5 (2015) 17781 and Z. Chen, L. Lin, X.
Cheng, E. Gjika, M. Keidar, Treatment of gastric cancer cells with
nonthermal atmospheric plasma generated in water, Biointerphases
11(3) (2016) 031010. Many studies of CAP for cancer treatment have
shown that CAP dose not harm normal tissues when applied at the
appropriate dosages. See, A. Shashurin, M. Keidar, S. Bronnikov,
R. Jujus, M. Stepp, Living tissue under treatment of cold plasma
atmospheric jet, Applied Physics Letters 93(18) (2008) 181501 and
S. N. Zucker, J. Zirnheld, A. Bagati, T. M. DiSanto, B. Des Soye,
J. A. Wawrzyniak, K. Etemadi, M. Nikiforov, R. Berezney,
Preferential induction of apoptotic cell death in melanoma cells
as compared with normal keratinocytes using a non-thermal plasma
torch, Cancer biology & therapy 13(13) (2012) 1299-1306. Taken
together, CAP therapy has been introduced as a cost effective,
rapid and selective treatment modality for killing cancer cells.
In addition, CAP with self-organized patterns has recently
attracted significant attentions on cancer therapy. Z. Chen, L.
Lin, E. Gjika, X. Cheng, J. Canady, M. Keidar, Selective treatment
of pancreatic cancer cells by plasma-activated saline solutions,
IEEE Transactions on Radiation and Plasma Medical Sciences (2017)
and Z. Chen, S. Zhang, I. Levchenko, I. I. Beilis, M. Keidar, In
vitro Demonstration of Cancer Inhibiting Properties from
Stratified Self-Organized Plasma-Liquid Interface, Scientific
reports 7(1) (2017) 12163.
[0009] Self-organization is generally referred to as a process of
spontaneous transition from a homogeneous stable state to a
regular pattern in a spatially extended system. See, Radehaus, C.,
Dirksmeyer, T., Willebrand, H. & Purwins, H.-G. Pattern
formation in gas discharge systems with high impedance electrodes.
Physics Letters A 125, 92-94 (1987) and Jäger, D., Baumann, H.
& Symanczyk, R. Experimental observation of spatial structures
due to current filament formation in silicon pin diodes. Physics
Letters A 117, 141-144 (1986). Self-organization is a complex and
fascinating phenomenon commonly observed in both natural and
technological contexts within diverse varieties of physics,
chemistry and biology. Raizer, Y. P. & Mokrov, M. Physical
mechanisms of self-organization and formation of current patterns
in gas discharges of the Townsend and glow types. Physics of
Plasmas 20, 101604 (2013) and Trelles, J. P. Formation of
self-organized anode patterns in arc discharge simulations. Plasma
Sources Science and Technology 22, 025017 (2013). Different types
of self-organization phenomena have been reported in a wide range
of plasmas, such as dielectric barrier discharge (see,
Kogelschatz, U. Filamentary, patterned, and diffuse barrier
discharges. IEEE Transactions on plasma science 30, 1400-1408
(2002)), high frequency discharge (see, Shi, J., Liu, D. &
Kong, M. G. Plasma stability control using dielectric barriers in
radio-frequency atmospheric pressure glow discharges. Applied
physics letters 89, 081502 (2006)), gas flow stabilized discharges
(see, Akishev, Y. et al. The influence of electrode geometry and
gas flow on corona-to-glow and glow-to-spark threshold currents in
air. Journal of Physics D: Applied Physics 34, 2875 (2001) and
Shirai, N., Ibuka, S. & Ishii, S. Atmospheric DC glow
discharge observed in intersecting miniature gas flows. IEEE
Transactions on Plasma Science 36, 960-961 (2008)), resistively
stabilized discharged (see, Laroussi, M., Alexeff, I., Richardson,
J. P. & Dyer, F. F. The resistive barrier discharge. IEEE
Transactions on Plasma Science 30, 158-159 (2002)), and discharges
with liquid electrodes (see, Laroussi, M., Lu, X. & Malott, C.
M. A non-equilibrium diffuse discharge in atmospheric pressure
air. Plasma Sources Science and Technology 12, 53 (2003), André,
P. et al. Experimental study of discharge with liquid non-metallic
(tap-water) electrodes in air at atmospheric pressure. Journal of
Physics D: Applied Physics 34, 3456 (2001) and Chen, Z., Zhang,
S., Levchenko, I., Beilis, I. I. & Keidar, M. In vitro
Demonstration of Cancer Inhibiting Properties from Stratified
Self-Organized Micro-Discharge Plasma-Liquid Interface. arXiv
preprint arXiv: 1701. 01655 (2017)). The self-organization
phenomena associated with the formation of electrode patterns are
significantly different among these discharges, which typically
occur in the anode or cathode layer. Benilov, M. Bifurcations of
current transfer through a collisional sheath with ionization and
self-organization on glow cathodes. Physical Review E 77, 036408
(2008) and Schoenbach, K. H., Moselhy, M. & Shi, W.
Self-organization in cathode boundary layer microdischarges.
Plasma Sources Science and Technology 13, 177 (2004).
Self-organization patterns (SOPs) of plasma include
square-textures, square-lattices, square/hexagonal superlattices,
hollow-hexagonal, multi-armed spirals, rotating-wheels patterns,
etc. Dong, L., Fan, W., He, Y. & Liu, F. Self-organized
gas-discharge patterns in a dielectric-barrier discharge system.
IEEE Transactions on Plasma Science 36, 1356-1357 (2008) and Dong,
L. et al. Collective vibration of discharge current filaments in a
self-organized pattern within a dielectric barrier discharge.
Physical Review E 85, 066403 (2012). The formation of these
patterns depends on various parameters such as driving current,
electrolyte conductivity, gap length, gas species, and so on. See,
Shirai, N., Uchida, S. & Tochikubo, F. Influence of oxygen gas
on characteristics of self-organized luminous pattern formation
observed in an atmospheric dc glow discharge using a liquid
electrode. Plasma Sources Science and Technology 23, 054010
(2014), Shirai, N., Ibuka, S. & Ishii, S. Self-organization
pattern in the anode spot of an atmospheric glow microdischarge
using an electrolyte anode and axial miniature helium flow.
Applied Physics Express 2, 036001 (2009) and Zheng, P. et al.
Self-organized pattern formation of an atmospheric-pressure, ac
glow discharge with an electrolyte electrode. Plasma Sources
Science and Technology 24, 015010 (2014). Recently, plasma
discharges with the liquid electrode have been studied referring
to applications ranging from water decontamination and activation
(see, Locke, B., Sato, M., Sunka, P., Hoffmann, M. & Chang,
J.-S. Electrohydraulic discharge and nonthermal plasma for water
treatment. Industrial & engineering chemistry research 45,
882-905 (2006) and Ostrikov, K. K., Cvelbar, U. & Murphy, A.
B. Plasma nanoscience: setting directions, tackling grand
challenges. Journal of Physics D: Applied Physics 44, 174001
(2011)), to nanoparticle and materials synthesis (Ostrikov, K. K.,
Cvelbar, U. & Murphy, A. B. Plasma nanoscience: setting
directions, tackling grand challenges. Journal of Physics D:
Applied Physics 44, 174001 (2011) and Richmonds, C. &
Sankaran, R. M. Plasma-liquid electrochemistry: rapid synthesis of
colloidal metal nanoparticles by microplasma reduction of aqueous
cations. Applied Physics Letters 93, 131501 (2008)), and medicine
(see, Kong, M. G. et al. Plasma medicine: an introductory review.
New Journal of Physics 11, 115012 (2009)). Therefore,
self-organization in plasma interacting with surfaces is interest
not only from a fundamental point of view as intrinsic and
fascinating characteristics of nature, but also from practical
standpoint in current and emerging technological applications.
SUMMARY OF THE INVENTION
[0010] The present invention creates plasma with different
self-organization patterns (SOPs) to activate saline solution. The
plasma activated saline solutions have anti-tumor effects on human
cancer cells.
[0011] Plasma interacting with the liquid generates reactive
oxygen species (ROS) and reactive nitrogen species (RNS) that act
as key intermediate for cancer therapy. See, Boehm, D., Heslin,
C., Cullen, P. J. & Bourke, P. Cytotoxic and mutagenic
potential of solutions exposed to cold atmospheric plasma.
Scientific reports 6 (2016); Chen, Z. et al. A Novel Micro Cold
Atmospheric Plasma Device for Glioblastoma Both In Vitro and In
Vivo. Cancers 9, 61 (2017). The present invention creates plasma
with different self-organization patterns (SOPs) to activate a
media such as saline solution. The plasma activated medias have
anti-tumor effects on human normal and cancer cells. A camera was
used to characterize the patterns of plasma with SOP. The spectra
of plasma with SOPs were determined by UV-visible-NIR optical
emission spectroscopy OES). The concentration of hydrogen peroxide
(H2 O2 ) and nitrite (NO2 − ) was measured by using a Fluorimetric
hydrogen peroxide assay kit, and the Griess reagent system,
respectively. The cell viability of H6c7 and BxPC-3 was measured
via Cell Counting KIT 8 Assay. Typically, saline solution is used
to treat dehydration by injection into a vein, and it is also used
to dilute medications to be given by injection. Based on the
results, one can suggest that SOP plasma-activated saline
solutions (plasma solutions) has the potential to be utilized as
an oral medicine or drug injected into tumors.
[0012] In a preferred embodiment, the present invention is a
method for manufacturing plasma-activated media for treatment of
cancer cells. The method comprises immersing a first electrode in
a media in a container, positioning a second electrode at a fixed
distance from a surface of the media in the container, and
applying electrical energy to the second electrode for a fixed
period of time, wherein the fixed distance and the fixed period of
time are selected to cause a plasma self-organized pattern at a
surface of the media with an atmospheric discharge between the
second electrode and the first electrode. The fixed distance
preferably is 4-6 mm. The fixed time may be, for example, 40
seconds...
US10479979
Method for making and Using Cold Atmospheric Plasma
Stimulated Media for Cancer Treatment
[ PDF ]
Abstract
A method for preparing cold atmospheric plasma stimulated cell
culture media with a cold atmospheric plasma system having a
delivery port out of which an inert gas flows. The inert gas may
be helium. The method comprises the steps of placing a cell
culture media in a first well, the first well having a bottom and
having a diameter greater than 20 mm; wherein the cell culture
media placed in the first well has a volume of 4 ml or less,
treating the cell culture media in the first well with cold
atmospheric plasma, wherein the treating is performed with a gap
between the delivery port and the bottom of the first well is
between 2.5 cm and 3.5 cm, and transferring a portion of the
treated media to cultured cancer cells in a second well. The cold
atmospheric plasma may be applied for 0.5 minutes to 2 minutes.